BioLineRx (BLRX) Other Accumulated Expenses (2011 - 2026)

BioLineRx's Other Accumulated Expenses history runs 15 years deep, the most recent figure standing at $1.7 million for Q4 2025.

• In Q4 2025, Other Accumulated Expenses fell 44.33% year-over-year to $1.7 million; the TTM figure through Dec 2025 stood at $1.7 million (down 44.33% YoY), while the FY2025 annual figure was $1.7 million, down 44.33% from the prior year.
• Other Accumulated Expenses for Q4 2025 stood at $1.7 million, down from $2.1 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $3.4 million in Q3 2024, with the low at $1.1 million in Q2 2021.
• The 5-year median for Other Accumulated Expenses is $1.9 million (2023), against an average of $2.0 million.
• The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses surged 99.65% in 2023, then plunged 44.33% in 2025.
• BioLineRx's Other Accumulated Expenses stood at $1.2 million in 2021, then surged by 42.14% to $1.7 million in 2022, then jumped by 92.26% to $3.4 million in 2023, then slipped by 6.62% to $3.1 million in 2024, then slumped by 44.33% to $1.7 million in 2025.
• Business Quant data shows BLRX's Other Accumulated Expenses at $1.7 million in Q4 2025, $2.1 million in Q3 2025, and $2.8 million in Q2 2025.